Curated News
By: NewsRamp Editorial Staff
April 28, 2026
Aclarion Hires Daniel Keefe to Lead Western U.S. Nociscan Growth
TLDR
- Aclarion appoints Daniel Keefe to drive Western U.S. growth, leveraging his proven track record to expand Nociscan adoption.
- Nociscan uses MRS, biomarkers, and AI to noninvasively identify painful discs, achieving 97% surgical success when all positive discs are treated.
- Aclarion's Nociscan helps physicians pinpoint chronic low back pain, improving treatment for 266 million people worldwide.
- Nociscan is the first cloud-based platform using chemical biomarkers to objectively locate pain sources in the spine.
Impact - Why it Matters
This news matters because chronic low back pain affects 266 million people worldwide, and Aclarion's Nociscan platform offers a noninvasive, AI-driven solution to precisely identify pain-generating discs, potentially improving surgical success rates to 97%. The appointment of a seasoned commercial leader like Daniel Keefe signals accelerating adoption and expanded access to this transformative diagnostic tool, directly impacting patients, spine surgeons, and healthcare systems seeking more effective treatment strategies for a debilitating condition.
Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, has appointed Daniel Keefe as Commercial Director, Western U.S. This strategic hire, announced via PRISM MediaWire, underscores the company's commitment to expanding its commercial footprint in a key region where Nociscan, its flagship SaaS platform, is experiencing triple-digit growth in utilization. Keefe brings over 20 years of medical device and healthcare technology sales experience, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical, with a proven track record of driving surgeon adoption and market expansion.
Dan will lead commercial efforts across the Western U.S., building on Aclarion’s existing presence in academic institutions and high-volume private practice spine centers. Brent Ness, CEO of Aclarion, highlighted Keefe's deep experience working with spine surgeons and hospital systems, stating, "Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies." Keefe himself expressed excitement about joining Aclarion at a time when Nociscan is gaining traction, noting its ability to provide objective insight into the source of pain, representing a significant advancement in chronic low back pain evaluation.
An estimated 266 million people worldwide live with chronic low back pain, making it one of the most pervasive health challenges. Aclarion’s Nociscan solution is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers associated with disc pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated. To find a Nociscan center, view our site map here.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, Aclarion Hires Daniel Keefe to Lead Western U.S. Nociscan Growth
